| Breast cancer cases (n = 48) | Healthy controls (n = 48) |
---|---|---|
Age (years) | Â | Â |
   Mean (± SD) | 58 (± 14) | 53 (± 9) |
Menopause status, n (%) | Â | Â |
   Pre | 16 (33) | - |
   Post | 30 (63) | - |
   Missing | 2 (4) | 48 (100) |
Sample storage duration (months) | Â | Â |
   Median (IQR) | 16 (11–35) | 17 (11–31) |
Time from diagnosis to blood sampling (days) | Â | Â |
   Median (IQR) | 7 (0–20) |  |
Stage, n (%) | Â | Â |
   IIA | 26 (54) |  |
   IIB | 11 (23) |  |
   IIIA | 6 (13) |  |
   IIIC | 5 (10) |  |
Tumor size, n (%) | Â | Â |
   > 0.5 – 1 cm | 2 (4) |  |
   > 1 – 2 cm | 16 (33) |  |
   > 2 – 5 cm | 28 (58) |  |
   > 5 cm | 2 (4) |  |
Lymph node involvement, n (%) | Â | Â |
   No | 9 (19) |  |
   1–3 | 29 (60) |  |
   > 3 | 10 (21) |  |
Differentiation, n (%) | Â | Â |
   High | 6 (13) |  |
   Intermediate | 19 (40) |  |
   Low | 22 (46) |  |
   Unknown | 1 (2) |  |
ER status, n (%) | Â | Â |
   Negative | 13 (27) |  |
   Positive | 35 (73) |  |
PR status, n (%) | Â | Â |
   Negative | 20 (42) |  |
   Positive | 28 (58) |  |
Her2/neu expression, n (%) | Â | Â |
   Negative | 36 (75) |  |
   Positive | 12 (25) |  |
P53 expression, n (%) | Â | Â |
   Negative | 18 (38) |  |
   Positive | 24 (50) |  |
   Missing | 6 (13) |  |